WO2000064483A3 - Releasable linkage and compositions containing same - Google Patents
Releasable linkage and compositions containing same Download PDFInfo
- Publication number
- WO2000064483A3 WO2000064483A3 PCT/US2000/010830 US0010830W WO0064483A3 WO 2000064483 A3 WO2000064483 A3 WO 2000064483A3 US 0010830 W US0010830 W US 0010830W WO 0064483 A3 WO0064483 A3 WO 0064483A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compositions containing
- containing same
- releasable linkage
- linkage
- releasable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Botany (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Polyethers (AREA)
Abstract
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2000/010830 WO2000064483A2 (en) | 1999-04-23 | 2000-04-21 | Releasable linkage and compositions containing same |
JP2000613473A JP2002542386A (en) | 1999-04-23 | 2000-04-21 | Releasable bonds and compositions containing the same |
IL14604700A IL146047A0 (en) | 1999-04-23 | 2000-04-21 | Releasable linkage and compositions containing same |
EP00923572A EP1173221A2 (en) | 1999-04-23 | 2000-04-21 | Releasable linkage and compositions containing same |
MXPA01010751A MXPA01010751A (en) | 1999-04-23 | 2000-04-21 | Releasable linkage and compositions containing same. |
NZ514990A NZ514990A (en) | 1999-04-23 | 2000-04-21 | Releasable linkage and compositions containing same |
AU43672/00A AU770390B2 (en) | 1999-04-23 | 2000-04-21 | Releasable linkage and compositions containing same |
CA002368793A CA2368793A1 (en) | 1999-04-23 | 2000-04-21 | Releasable linkage and compositions containing same |
NO20015169A NO20015169L (en) | 1999-04-23 | 2001-10-23 | Compound with reversible bond and preparation comprising the compound |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13089799P | 1999-04-23 | 1999-04-23 | |
US60/130,897 | 1999-04-23 | ||
PCT/US2000/010830 WO2000064483A2 (en) | 1999-04-23 | 2000-04-21 | Releasable linkage and compositions containing same |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000064483A2 WO2000064483A2 (en) | 2000-11-02 |
WO2000064483A3 true WO2000064483A3 (en) | 2001-08-02 |
Family
ID=34107071
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/010830 WO2000064483A2 (en) | 1999-04-23 | 2000-04-21 | Releasable linkage and compositions containing same |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1173221A2 (en) |
JP (1) | JP2002542386A (en) |
AU (1) | AU770390B2 (en) |
CA (1) | CA2368793A1 (en) |
IL (1) | IL146047A0 (en) |
NO (1) | NO20015169L (en) |
NZ (1) | NZ514990A (en) |
WO (1) | WO2000064483A2 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4558952B2 (en) | 1999-04-23 | 2010-10-06 | アルザ コーポレイション | Complexes with cleavable bonds for use in liposomes |
US7303760B2 (en) | 1999-04-23 | 2007-12-04 | Alza Corporation | Method for treating multi-drug resistant tumors |
US7238368B2 (en) | 1999-04-23 | 2007-07-03 | Alza Corporation | Releasable linkage and compositions containing same |
US7455855B2 (en) | 2000-04-03 | 2008-11-25 | Santen Pharmaceutical Co., Ltd. | Delivering substance and drug delivery system using the same |
JP2004525138A (en) | 2001-03-26 | 2004-08-19 | アルザ・コーポレーシヨン | Liposomal compositions for improved intracellular delivery of therapeutic agents |
KR20070019941A (en) * | 2003-09-03 | 2007-02-16 | 교와 핫꼬 고교 가부시끼가이샤 | Compound modified with glycerol derivative |
TW200616604A (en) | 2004-08-26 | 2006-06-01 | Nicholas Piramal India Ltd | Nitric oxide releasing prodrugs containing bio-cleavable linker |
JP7022328B2 (en) | 2017-03-30 | 2022-02-18 | 日油株式会社 | Hydrophilic polymer derivative with self-destructive acetal linker and complex using it |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5891468A (en) * | 1996-10-11 | 1999-04-06 | Sequus Pharmaceuticals, Inc. | Fusogenic liposome compositions and method |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4952394A (en) * | 1987-11-23 | 1990-08-28 | Bristol-Myers Company | Drug-monoclonal antibody conjugates |
-
2000
- 2000-04-21 IL IL14604700A patent/IL146047A0/en active IP Right Grant
- 2000-04-21 JP JP2000613473A patent/JP2002542386A/en active Pending
- 2000-04-21 NZ NZ514990A patent/NZ514990A/en unknown
- 2000-04-21 AU AU43672/00A patent/AU770390B2/en not_active Ceased
- 2000-04-21 WO PCT/US2000/010830 patent/WO2000064483A2/en active IP Right Grant
- 2000-04-21 EP EP00923572A patent/EP1173221A2/en not_active Ceased
- 2000-04-21 CA CA002368793A patent/CA2368793A1/en not_active Abandoned
-
2001
- 2001-10-23 NO NO20015169A patent/NO20015169L/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5891468A (en) * | 1996-10-11 | 1999-04-06 | Sequus Pharmaceuticals, Inc. | Fusogenic liposome compositions and method |
Non-Patent Citations (10)
Title |
---|
GABER MOHAMED H ET AL: "Thermosensitive sterically stabilized liposomes: Formulation and in vitro studies on mechanism of doxorubicin release by bovine serum and human plasma.", PHARMACEUTICAL RESEARCH (NEW YORK), vol. 12, no. 10, 1995, pages 1407 - 1416, XP000979539, ISSN: 0724-8741 * |
HIROTA SADAO: "Physicochemical specification of drug carrying liposomes for the quality control in the industrial production.", INTERNATIONAL JOURNAL OF PHARMACEUTICS (AMSTERDAM), vol. 162, no. 1-2, 20 March 1998 (1998-03-20), pages 185 - 194, XP000979551, ISSN: 0378-5173 * |
JOHNSSON MARKUS ET AL: "Optimization of drug loading procedures and characterization of liposomal formulations of two novel agents intended for boron neutron capture therapy (BNCT).", JOURNAL OF LIPOSOME RESEARCH, vol. 9, no. 1, February 1999 (1999-02-01), pages 53 - 79, XP000805700, ISSN: 0898-2104 * |
KIRPOTIN DMITRI ET AL: "Liposomes with detachable polymer coating: Destabilization and fusion of dioleoylphosphatidylethanolamine vesicles triggered by cleavage of surface-grafted poly(ethylene glycol).", FEBS LETTERS, vol. 388, no. 2-3, 1996, pages 115 - 118, XP002080855, ISSN: 0014-5793 * |
MUELLER C E ET AL: "AMPHIPHILIC UNSYMMETRICAL DISULFIDES AS BILAYER-FORMING COMPOUNDS", ARCHIV DER PHARMAZIE (WEINHEIM), vol. 322, no. 6, 1989, pages 343 - 350, XP000981914, ISSN: 0365-6233 * |
VAAGE J ET AL: "THERAPY OF PRIMARY AND METASTATIC MOUSE MAMMARY CARCINOMAS WITH DOXORUBICIN ENCAPSULATED IN LONG CIRCULATING LIPOSOMES", INTERNATIONAL JOURNAL OF CANCER, vol. 51, no. 6, 1992, pages 942 - 948, XP000979548, ISSN: 0020-7136 * |
VAAGE JAN ET AL: "Therapy of a xenografted human colonic carcinoma using cisplatin or doxorubicin encapsulated in long-circulating pegylated stealth liposomes.", INTERNATIONAL JOURNAL OF CANCER, vol. 80, no. 1, 5 January 1999 (1999-01-05), pages 134 - 137, XP000979545, ISSN: 0020-7136 * |
VAAGE JAN ET AL: "Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes.", CANCER (PHILADELPHIA), vol. 72, no. 12, 1993, pages 3671 - 3675, XP000979540, ISSN: 0008-543X * |
VAAGE JAN ET AL: "Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts.", CANCER (PHILADELPHIA), vol. 73, no. 5, 1994, pages 1478 - 1484, XP000979547, ISSN: 0008-543X * |
ZALIPSKY SAMUEL ET AL: "New detachable poly(ethylene glycol) conjugates: Cysteine-cleavable lipopolymers regenerating natural phospholipid, diacyl phosphatidylethanolamine.", BIOCONJUGATE CHEMISTRY, vol. 10, no. 5, 20 September 1999 (1999-09-20), pages 703 - 707, XP002159601, ISSN: 1043-1802 * |
Also Published As
Publication number | Publication date |
---|---|
AU770390B2 (en) | 2004-02-19 |
EP1173221A2 (en) | 2002-01-23 |
NO20015169D0 (en) | 2001-10-23 |
NO20015169L (en) | 2001-12-19 |
AU4367200A (en) | 2000-11-10 |
IL146047A0 (en) | 2002-07-25 |
JP2002542386A (en) | 2002-12-10 |
CA2368793A1 (en) | 2000-11-02 |
NZ514990A (en) | 2004-01-30 |
WO2000064483A2 (en) | 2000-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1041820A1 (en) | Conjugate having a cleavable linkage for use in a liposome | |
CA2395331A1 (en) | Pharmaceutical compositions providing enhanced drug concentrations | |
CA2306106A1 (en) | Biostatic coatings for the reduction and prevention of bacterial adhesion | |
CA2197188A1 (en) | Denture adhesive | |
CA2316834A1 (en) | Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom | |
CA2222535A1 (en) | Oxygen-scavenging composition | |
CA2430540A1 (en) | Antimicrobial hot melt adhesive | |
AU6020494A (en) | Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents | |
CA2131547A1 (en) | Composition for oral preparations | |
CA2307607A1 (en) | Powdery nasal compositions | |
CA2268433A1 (en) | Improved interferon polymer conjugates | |
CA2327723A1 (en) | Bicyclic hydroxamic acid derivatives | |
CA2195426A1 (en) | Aqueous silane adhesive compositions | |
CA2203895A1 (en) | Denture stabilizing compositions | |
CA2435276A1 (en) | Syntactic deformable foam compositions and methods for making | |
CA2169401A1 (en) | Components and catalysts for the polymerization of olefins | |
CA2191971A1 (en) | Pegylation reagents and compounds formed therewith | |
AU6535900A (en) | Compositions containing a biocidal compound or an adsorbent and/or catalyst compound and methods of making and using therefor | |
AU7522098A (en) | Fungicidal active compound combinations | |
WO2000076550A3 (en) | Carrier-drug conjugate | |
CA2392790A1 (en) | Operator selected maximum speed and recalibrated pedal range for a vehicle | |
WO2000064483A3 (en) | Releasable linkage and compositions containing same | |
AU2268301A (en) | Novel urea compounds, compositions and methods of use and preparation | |
AU8366398A (en) | Trifunctional reagent for conjugation to a biomolecule | |
EP1003526A4 (en) | Covalently linked n,o-carboxymethylchitosan and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 00807707.X Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
ENP | Entry into the national phase |
Ref document number: 2368793 Country of ref document: CA Ref document number: 2368793 Country of ref document: CA Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2000 613473 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001/08724 Country of ref document: ZA Ref document number: 514990 Country of ref document: NZ Ref document number: PA/a/2001/010751 Country of ref document: MX Ref document number: 200108724 Country of ref document: ZA Ref document number: 1020017013588 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000923572 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017013588 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2000923572 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 1020017013588 Country of ref document: KR |